Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Bob Löwenberg, Jorge Sierra et al.|Blood|2022Cited by 3k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Courtney D. DiNardo et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M. Stein, Martin S. Tallman, Guillermo Garcia‐Manero et al.|Blood|2018Cited by 457
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C. Issa, Eytan M. Stein|Nature|2023Cited by 450